JP2006522124A - プロテインキナーゼのインヒビターとして有用な組成物 - Google Patents

プロテインキナーゼのインヒビターとして有用な組成物 Download PDF

Info

Publication number
JP2006522124A
JP2006522124A JP2006509283A JP2006509283A JP2006522124A JP 2006522124 A JP2006522124 A JP 2006522124A JP 2006509283 A JP2006509283 A JP 2006509283A JP 2006509283 A JP2006509283 A JP 2006509283A JP 2006522124 A JP2006522124 A JP 2006522124A
Authority
JP
Japan
Prior art keywords
compound
compound according
optionally substituted
disease
chromen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522124A5 (enExample
Inventor
ジェレミー グリーン，
アレックス アロノフ，
アルバート シー． ピアース，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2006522124A publication Critical patent/JP2006522124A/ja
Publication of JP2006522124A5 publication Critical patent/JP2006522124A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
JP2006509283A 2003-04-03 2004-03-25 プロテインキナーゼのインヒビターとして有用な組成物 Pending JP2006522124A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46004203P 2003-04-03 2003-04-03
PCT/US2004/009145 WO2004092154A1 (en) 2003-04-03 2004-03-25 Compositions useful as inhibitors of protein kinases

Publications (2)

Publication Number Publication Date
JP2006522124A true JP2006522124A (ja) 2006-09-28
JP2006522124A5 JP2006522124A5 (enExample) 2007-05-17

Family

ID=33299701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509283A Pending JP2006522124A (ja) 2003-04-03 2004-03-25 プロテインキナーゼのインヒビターとして有用な組成物

Country Status (6)

Country Link
US (1) US7547794B2 (enExample)
EP (1) EP1615906A1 (enExample)
JP (1) JP2006522124A (enExample)
AU (1) AU2004230841A1 (enExample)
CA (1) CA2522595A1 (enExample)
WO (1) WO2004092154A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503618A (ja) * 2012-01-10 2015-02-02 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
JP2018534259A (ja) * 2015-09-24 2018-11-22 ベネボレントエーアイ バイオ リミテッド 神経変性疾患の処置

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RS53109B (sr) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
EP2332527A3 (en) * 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006063164A2 (en) * 2004-12-08 2006-06-15 Wisconsin Alumni Research Foundation Compositions and methods for treating neuroendocrine tumors
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US8026278B2 (en) * 2005-05-27 2011-09-27 Smith Brian R Inhibitors of pyruvate kinase as therapeutic agents for cancer
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
DE602005000514T2 (de) * 2005-06-17 2007-10-25 Magneti Marelli Powertrain S.P.A. Brennstoffeinspritzventil
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP2009528381A (ja) * 2006-02-28 2009-08-06 パロマ ファーマシューティカルズ，インク． 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
ATE517126T1 (de) 2006-03-20 2011-08-15 Seikagaku Kogyo Co Ltd Therapeutikum für rheumatoide arthritis
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジン−２−アミン化合物およびｊａｋキナーゼの阻害剤としてのその使用
JPWO2009110415A1 (ja) 2008-03-03 2011-07-14 武田薬品工業株式会社 併用剤
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
AU2009228303B2 (en) * 2008-03-25 2015-08-13 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
EP2323649A4 (en) * 2008-07-25 2011-09-07 Univ Emory TREATMENT OF VARIOUS DISORDERS WITH 7,8-DIHYDROXY FLAVONE AND ITS DERIVATIVES
US20100055099A1 (en) * 2008-08-29 2010-03-04 Ellen Filvaroff Diagnostics and Treatments for VEGF-Independent Tumors
WO2010075286A1 (en) * 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
EP2396307B1 (en) 2009-02-11 2014-10-15 Merck Patent GmbH Novel amino azaheterocyclic carboxamides
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011017009A1 (en) 2009-08-07 2011-02-10 Merck Patent Gmbh Novel azaheterocyclic compounds
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
WO2011156479A2 (en) 2010-06-09 2011-12-15 Emory University Trkb agonists and methods of use
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2012149048A1 (en) * 2011-04-26 2012-11-01 Indiana University Research And Technology Corporation Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of lyp
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
MX347241B (es) 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
EP2755965B1 (en) 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
CA2856301C (en) 2011-11-23 2020-10-06 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
AU2012355494B2 (en) 2011-12-22 2017-07-13 Merck Patent Gmbh Novel heterocyclic carboxamides as modulators of kinase activity
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN104487429B (zh) 2012-07-27 2017-07-14 爱默蕾大学 杂环黄酮衍生物、组合物及与其相关的方法
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
ES2656096T3 (es) 2012-11-16 2018-02-23 Merck Patent Gmbh Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CA2887539C (en) 2012-11-29 2021-10-26 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
AU2014228385B2 (en) 2013-03-11 2018-08-09 Merck Patent Gmbh 6-[4-(1-H-imidazol-2-yl]piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR102410696B1 (ko) 2014-04-03 2022-06-17 메르크 파텐트 게엠베하 암 치료법의 조합
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3186257B1 (en) 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
HRP20192250T1 (hr) 2015-08-27 2020-05-15 Prexton Therapeutics Sa Derivat kromon oksima koji prodire u mozak za liječenje diskinezije uzrokovane levodopom
EP3260445A1 (en) * 2016-06-24 2017-12-27 Universität Konstanz Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3502095A1 (en) 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
HUE067471T2 (hu) 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50135224A (enExample) * 1974-04-01 1975-10-27
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1998017662A1 (en) * 1996-10-18 1998-04-30 Novartis Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
WO2001053266A1 (en) * 2000-01-24 2001-07-26 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
WO2004039793A1 (en) * 2002-11-01 2004-05-13 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065574A (en) * 1975-08-29 1977-12-27 The Upjohn Company New method for controlling fungi using 4-chromone, 4-chromanone, 4-chromone oxime and 4-chromanone oxime compounds
FR2721027B1 (fr) * 1994-06-08 1996-07-19 Adir Nouveaux dérivés tétracycliques de la 1,4-oxazine, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CN1093086C (zh) * 1999-09-08 2002-10-23 复旦大学 表面活性剂作辅助剂的emt沸石的合成方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50135224A (enExample) * 1974-04-01 1975-10-27
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1998017662A1 (en) * 1996-10-18 1998-04-30 Novartis Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
WO2001053266A1 (en) * 2000-01-24 2001-07-26 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
WO2004039793A1 (en) * 2002-11-01 2004-05-13 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5006006003, ＳＥＮ， Ａ． Ｂ．, ＪＯＵＲＮＡＬ ＯＦ ＴＨＥ ＩＮＤＩＡＮ ＣＨＥＭＩＣＡＬ ＳＯＣＩＥＴＹ, 1960, Ｖ４, Ｐ２１７−２２２ *
JPN5006006004, ＢＥＵＧＥＬＭＡＮＳ， Ｒ．, ＪＯＵＲＮＡＬ ＯＦ ＯＲＧＡＮＩＣ ＣＨＥＭＩＳＴＲＹ, 1977, Ｖ４２ Ｎ８, Ｐ１３５６−１３６０, US, ＡＭＥＲＩＣＡＮ ＣＨＥＭＩＣＡＬ ＳＯＣＩＥＴＹ *
JPN6010039093, ＥＤＷＡＲＤＳ，Ｊ．Ｍ． ｅｔ ａｌ, "Ａｎｔｉｔｕｍｏｒ ｐｌａｎｔｓ． Ｐａｒｔ ＶＩＩ． Ａｎｔｉｎｅｏｐｌａｓｔｉｃ ａｃｔｉｖｉｔｙ ａｎｄ ｃｙｔｏｔｏｘｉｃｉｔｙ ｏｆ ｆｌａｖｏｎｅｓ， ｉｓｏｆｌａｖｏｎｅｓ， ａｎｄ", Ｊｏｕｒｎａｌ ｏｆ Ｎａｔｕｒａｌ Ｐｒｏｄｕｃｔｓ, 1979, Ｖｏｌ．４２， Ｎｏ．１, ｐｐ．８５−９１ *
JPN6010039094, Ｗ Ｂａｓｉｎｓｋｉ, "Ｂｅｎｚ−γ−ｐｙｒｏｎｅｓ， Ｐａｒｔ ＸＩＶ．", Ｐｏｌｉｓｈ ｊｏｕｒｎａｌ ｏｆ ｃｈｅｍｉｓｔｒｙ, 1991, Ｖｏｌ．６５， Ｎｏ．９−１０, ｐｐ．１６１９−１６３２ *
JPN6010039096, Ｖ．Ｖ．Ｉｓｈｃｈｅｎｋｏ ｅｔ ａｌ．, "Ａｍｉｎｏ ａｃｉｄ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｏｘｉｍｅｓ ｏｆ ｆｌａｖｏｎｅｓ", Ｃｈｅｍｉｓｔｒｙ ｏｆ ｈｅｔｅｒｏｃｙｃｌｉｃ ｃｏｍｐｏｕｎｄｓ, 2002, Ｖｏｌ．３８， Ｎｏ．３, ｐｐ．２７４−２８０ *
JPN6010039097, Ｖ．Ｐ．Ｋｈｉｌｙａ ｅｔ ａｌ．, "Ｔｈｉａｚｏｌｅ ａｎａｌｏｇｓ ｏｆ ｉｓｏｆｌａｖｏｎｅｓ", Ｋｈｉｍｉｃｈｎｉ ｔａ ｂｉｏｌｏｇｉｃｈｎｉ ｎａｕｋｉ, 1980, （５）, ｐｐ．６１−６６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503618A (ja) * 2012-01-10 2015-02-02 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
JP2018534259A (ja) * 2015-09-24 2018-11-22 ベネボレントエーアイ バイオ リミテッド 神経変性疾患の処置

Also Published As

Publication number Publication date
US20040198750A1 (en) 2004-10-07
WO2004092154A1 (en) 2004-10-28
AU2004230841A1 (en) 2004-10-28
US7547794B2 (en) 2009-06-16
EP1615906A1 (en) 2006-01-18
CA2522595A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
JP2006522124A (ja) プロテインキナーゼのインヒビターとして有用な組成物
EP1581526B1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
EP1562911B1 (en) Compositions useful as inhibitors of jak and other protein kinases
DK2649066T3 (en) Hydantoin derivatives using as KV3 inhibitors.
AU2015250610B2 (en) Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
DE69836332T2 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosin kinasen, insbesondere von raf kinasen
JP6660182B2 (ja) ピラゾロ化合物及びその使用
JP4741948B2 (ja) プロテインキナーゼインヒビターおよびそれらの使用
TWI714527B (zh) 醯胺類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
EP1562938B1 (en) Heteroaryl-pyrimidine derivatives as jak inhibitors
DE602004010151T2 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
JP4808154B2 (ja) プロテインキナーゼインヒビターとして有用な組成物
WO2005007099A2 (en) Pkb inhibitors as anti-tumor agents
TW201506028A (zh) １，２-雙取代雜環化合物
EP1507779A1 (en) Inhibitors of jak and cdk2 protein kinases
CN103570625A (zh) N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2011135259A1 (fr) Dérivés de pyrido[3,2-d]pyrimidine, leurs procédés de préparation et leurs utilisations thérapeutiques
RS54567B1 (sr) 1h-indazol-3-karboksamidna jedinjenja kao inhibitori 3-beta kinaze glikogen sintetaze
EA024295B1 (ru) N-[4-(1H-ПИРАЗОЛО[3,4-b]ПИРАЗИН-6-ИЛ)ФЕНИЛ]СУЛЬФОНАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ
WO2013056015A1 (en) Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
RS54539B1 (sr) Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze
CN104995182A (zh) 被取代的喹喔啉衍生物及其作为mGluR4的正变构调节剂的用途
JP2007506763A (ja) プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
CN104955826A (zh) 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物
US7601718B2 (en) Compositions useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101202